Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Hans Schuller

Pulmonary Disease Slidell, LA Medical Doctor

NPI 1407857568 CMS profile 1001150

2240 Gause Blvd E, Slidell, LA 70461

Open in the dashboard

General payments

$10,065

589 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Hans Schuller of Slidell, LA is reported in the CMS Open Payments database as having received $10,065 across 589 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $1,033 49
2023 General $1,463 80
2022 General $1,811 111
2021 General $2,037 127
2020 General $1,817 108
2019 General $1,903 114

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hans Schuller
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Hans Schuller were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Hans Schuller Pulmonary Disease median Middle half National median
2019 $1,903 $377 $109–$1,340 $163
2020 $1,817 $230 $56–$907 $114
2021 $2,037 $269 $68–$1,072 $132
2022 $1,811 $390 $100–$1,457 $149
2023 $1,463 $419 $114–$1,659 $160
2024 $1,033 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. GlaxoSmithKline, LLC. $2,928 181 payments
  2. AstraZeneca Pharmaceuticals LP $1,619 89 payments
  3. Grifols USA, LLC $831 44 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $600 42 payments
  5. Mylan Specialty L.P. $551 30 payments
  6. Insmed, Inc. $418 26 payments
  7. Jazz Pharmaceuticals Inc. $357 18 payments
  8. Amgen Inc. $246 14 payments
  9. Amneal Pharmaceuticals LLC $227 13 payments
  10. Axsome Therapeutics, Inc. $207 7 payments
  11. Other $2,081 125 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $10,065 589 payments
Products named General payments · program years 2019–2024
  1. TRELEGY ELLIPTA $2,172 138 payments
  2. Prolastin-C Liquid $831 44 payments
  3. BREZTRI $606 29 payments
  4. SPIRIVA RESPIMAT $590 44 payments
  5. SYMBICORT $554 24 payments
  6. Arikayce $418 26 payments
  7. YUPELRI $387 19 payments
  8. FASENRA $294 16 payments
  9. STIOLTO RESPIMAT $280 21 payments
  10. SUNOSI $277 14 payments
  11. Other $5,633 329 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,237

Median for Pulmonary Disease: 936

Drug cost

$354,074

Median for Pulmonary Disease: $487,987

Branded share of claims

48.3%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 253 $269,228
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 16 $21,235
Symbicort Budesonide/Formoterol Fumarate Brand 62 $17,866
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 21 $17,851
Breo Ellipta Fluticasone/Vilanterol Brand 14 $8,428
Albuterol Sulfate Hfa Albuterol Sulfate Brand 117 $5,934
Fluticasone Propionate Generic 88 $2,380
Ventolin Hfa Albuterol Sulfate Brand 16 $1,587
Doxycycline Hyclate Generic 102 $1,579
Gabapentin Generic 73 $1,254

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$72,694

Medicare's payments for the services billed

Medicare patients

512

Average age 73

Services billed

1,090

269 women, 243 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 41%
Ischemic heart disease 38%
COPD 35%
Chronic kidney disease 25%
Depression 24%
Atrial fibrillation 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $374
$374 253 —
AREXVY
  • GlaxoSmithKline, LLC. $125
$125 — —
Prolastin-C Liquid
  • Grifols USA, LLC $92
$92 — —
YUPELRI
  • Mylan Specialty L.P. $88
$88 — —
UNITHROID
  • Amneal Pharmaceuticals LLC $72
$72 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

589 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record